We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults
PeriodicalsMedical Sciences

Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults

Checking your access to this record.

Abstract & Overview

-host disease (GvHD) in its acute and chronic forms continues to represent a significant barrier to the success and wide-applicability of blood and marrow transplantation as a potentially curative treatment modality for a number of benign and malignant blood conditions. Presently, calcineurin inhibitor (CNI)-based regimens remain the most commonly used prevention strategy, although post-transplant cyclophosphamide is emerging as an alternative approach, and is providing a backbone for innovative CNI-free combinations. In this paper, we review the current strategies used for the prevention of GvHD, and highlight some of the developing and promising combinations.

Cite this record

Cosmin Tegla, Jun‐Yong Choi, Maher Abdul‐Hay, Frank Cirrone, Kelli Cole, A. Samer Al‐Homsi (2020). Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults. Clinical Hematology International, 2(1), 5–5. https://doi.org/10.2991/chi.d.200115.001

Copy in another style

Tegla, C., Choi, J., Abdul‐Hay, M., Cirrone, F., Cole, K., & Al‐Homsi, A. S. (2020). Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults. Clinical Hematology International, 2(1), 5–5. https://doi.org/10.2991/chi.d.200115.001
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.